Abstract
Background Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and responses to therapy have been identified. Classification as “hyperinflammatory” or “hypoinflammatory” depends on plasma biomarker profiling. Differences in pulmonary biology underlying these phenotypes are unknown.
Methods We analyzed tracheal aspirate (TA) RNA sequencing (RNASeq) data from 41 ARDS patients and 5 mechanically ventilated controls to assess differences in lung inflammation and repair between ARDS phenotypes. In a subset of subjects, we also analyzed plasma proteomic data. We performed single-cell RNA sequencing (scRNASeq) on TA samples from 9 ARDS patients. We conducted differential gene expression and gene set enrichment analyses, in silico prediction of pharmacologic treatments, and compared results to experimental models of acute lung injury.
Findings In bulk RNASeq data, 1334 genes were differentially expressed between ARDS phenotypes (false detection rate < 0.1). Hyperinflammatory ARDS was characterized by an exaggerated innate immune response, increased activation of the integrated stress response, interferon signaling, apoptosis, and T-cell activation. Gene sets from experimental models of lipopolysaccharide lung injury overlapped more strongly with hyperinflammatory than hypoinflammatory ARDS, though overlap in gene expression between experimental and clinical samples was variable. ScRNASeq demonstrated a central role for T-cells in the hyperinflammatory phenotype. Plasma proteomics confirmed a role for innate immune activation, interferon signaling, and T-cell activation in the hyperinflammatory phenotype. Predicted candidate therapeutics for the hyperinflammatory phenotype included imatinib and dexamethasone.
Interpretation Hyperinflammatory and hypoinflammatory ARDS phenotypes have distinct respiratory tract biology, which could inform targeted therapeutic development.
Funding National Institutes of Health; University of California San Francisco ImmunoX CoLabs; Chan Zuckerberg Foundation; Genentech
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the NIH: F32HL151117 (AS), R35HL140026 (CSC), 2R24AA019661-06A1 (CSC), NIH/NHLBI K23HL138461-01A1 (CRL), U19 AI1077439 (DJE, CSC). Additional funding from: UCSF ImmunoX CoLabs, Chan Zuckerberg Foundation 2019-202665, Genentech TSK-020586
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These studies were approved by the UCSF Institutional Review Board (17-24056, 20-30497), which granted an initial waiver of informed consent to collect TA and blood samples within 48 hours of ICU admission. Informed consent was then obtained from patients or surrogates.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript has been significantly revised to incorporate new single-cell RNA sequencing data and analyses, which highlight the central role of T cells and interferon-stimulated immune responses in hyperinflammatory ARDS. The sections on bulk RNA sequencing have been revised to highlight additional differences between the phenotypes and controls. The manuscript now focuses on the host response and the sections on metatranscriptomic differences has been removed.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
